LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

LLY

748.08

-0.86%↓

JNJ

177.42

-0.37%↓

ABBV

217.75

-0.25%↓

UNH

347.95

-1.4%↓

AZN

78.06

-1.86%↓

Search

Anavex Life Sciences Corp

Cerrado

SectorSanidad

9.1 -2.67

Resumen

Variación precio

24h

Actual

Mínimo

8.82

Máximo

9.49

Métricas clave

By Trading Economics

Ingresos

-2M

-13M

Empleados

42

EBITDA

-2.1M

-13M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+348.24% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-88M

881M

Apertura anterior

11.77

Cierre anterior

9.1

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

183 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Anavex Life Sciences Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

15 sept 2025, 22:39 UTC

Adquisiciones, fusiones, absorciones

CSL Agrees to Deal to Advance Coagulation Treatment, May Acquire Developer

15 sept 2025, 16:43 UTC

Principales Movimientos del Mercado

Strive Shares Sink on Board Disclosure; Bitcoin Treasury Strategy

15 sept 2025, 16:42 UTC

Principales Movimientos del Mercado

Helius Medical Tech Jumps on Funding to Launch Solana Treasury

15 sept 2025, 16:35 UTC

Principales Movimientos del Mercado

Chegg to Pay $7.5 Million to Settle FTC Claims Over Subscription Cancellation Process

15 sept 2025, 23:46 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 sept 2025, 23:46 UTC

Charlas de Mercado

Nikkei May Rise as Fed Rate Cut Hopes Support Stocks -- Market Talk

15 sept 2025, 23:34 UTC

Charlas de Mercado

Gold Steady Ahead of FOMC Meeting, Major U.S. Economic Data -- Market Talk

15 sept 2025, 22:48 UTC

Charlas de Mercado

FOMC May Opt to Play Catch Up With Rate Cuts -- Market Talk

15 sept 2025, 22:12 UTC

Adquisiciones, fusiones, absorciones

CSL Expects Commercial Launch in 2029

15 sept 2025, 22:12 UTC

Adquisiciones, fusiones, absorciones

CSL Says VarmX to Receive Further Commercial Milestones Afterwards

15 sept 2025, 22:11 UTC

Adquisiciones, fusiones, absorciones

CSL Says VarmX to Receive Payments of Up to $388 Million Up to Launch of VMX-C001

15 sept 2025, 22:11 UTC

Adquisiciones, fusiones, absorciones

CSL to Have Right to Exercise Option Based on Phase 3 Data

15 sept 2025, 22:10 UTC

Adquisiciones, fusiones, absorciones

CSL to Make Upfront Payment to VarmX of $117 Million for Exclusive Option to Acquire Company

15 sept 2025, 21:16 UTC

Adquisiciones, fusiones, absorciones

Chord Energy: Assets Have a Low Avg NYMEX WTI Breakeven and Are Immediately Competitive for Capital

15 sept 2025, 21:16 UTC

Adquisiciones, fusiones, absorciones

Chord Energy: Assets Have Significant Overlap With Existing Footprint, Setting the Stage for Long-Lateral Development

15 sept 2025, 21:15 UTC

Adquisiciones, fusiones, absorciones

Chord Energy to Buy 48,000 Net Acres in the Williston Core

15 sept 2025, 21:14 UTC

Adquisiciones, fusiones, absorciones

Chord Energy to Buy Assets in Williston Basin From Exxon's XTO Energy and Affiliates for $550M

15 sept 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

15 sept 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

15 sept 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

15 sept 2025, 19:29 UTC

Charlas de Mercado

U.S. Natural Gas Gains on Warmer Weather Outlook -- Market Talk

15 sept 2025, 19:14 UTC

Charlas de Mercado

Attacks on Russia Lifts Oil Price Despite Shaky Fundamentals -- Market Talk

15 sept 2025, 18:16 UTC

Charlas de Mercado

Gold Powers to New High -- Market Talk

15 sept 2025, 18:05 UTC

Charlas de Mercado

Easing Autonomous Vehicle Regulations Will Begin Tesla's Next Chapter -- Market Talk

15 sept 2025, 17:50 UTC

Adquisiciones, fusiones, absorciones

U.S. Reaches Outline of Deal With China Over TikTok -- 2nd Update

15 sept 2025, 17:10 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 sept 2025, 17:10 UTC

Charlas de Mercado

S&P Expects Fed, BOC to Cut Rates -- Market Talk

15 sept 2025, 16:52 UTC

Charlas de Mercado

Copper Climbs as Traders Brace for U.S. Rate Cut -- Market Talk

15 sept 2025, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

15 sept 2025, 16:20 UTC

Charlas de Mercado
Ganancias

Auto & Transport Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Anavex Life Sciences Corp previsión

Precio Objetivo

By TipRanks

348.24% repunte

Estimación a 12 Meses

Media 42 USD  348.24%

Máximo 42 USD

Mínimo 42 USD

De acuerdo con 1 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Anavex Life Sciences Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

1 ratings

1

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

8.275 / 9.312Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

183 / 371 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
help-icon Live chat